grant
Defining mechanisms of action of Menin inhibition in AML
Organization DANA-FARBER CANCER INSTLocation BOSTON, UNITED STATESPosted 25 Apr 1997Deadline 31 Aug 2030
NIHUS FederalResearch GrantFY20250-11 years old21+ years oldALL1ALL1 geneAML - Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia Protein 1Acute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAcute leukemiaAdultAdult HumanApoptosisApoptosis PathwayAreaB23B23 Nuclear Matrix ProteinBindingCXXC7Cell LineCellLineChildChild YouthChildhoodChildren (0-21)Chimera ProteinChimeric ProteinsChromatinChromatin LoopChromatin Loop DomainsChromatin StructureClinicalClinical ResearchClinical StudyClinical TrialsComplexCpG IslandsCpG-Rich IslandsDNA LoopDNA MethylationDNA mutationDataDevelopmentDevelopmental GeneDiagnosisDiseaseDisorderDrosophila Homolog of TrithoraxDrug CombinationsDrug TargetingE3 LigaseE3 Ubiquitin LigaseEarly-Stage Clinical TrialsEnzyme GeneEnzymesEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEventFDA approvedFusion ProteinGene Action RegulationGene ExpressionGene Expression RegulationGene RegulationGene Regulation ProcessGene TranscriptionGenesGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGenomicsHOX geneHRXHomeo Box GenesHomeobox Family GeneHomeobox GenesHomeodoamin GeneHomeotic GenesHumanIn VitroKMT2ALeadLysine-Specific Methyltransferase 2AMEIS1MEIS1 geneMLL geneMLL1MaintenanceMalignantMalignant - descriptorMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMediatingMedicalMeis homeobox 1MeninMetabolic Protein DegradationMethodsMixed Lineage Leukemia GeneMixed-Lineage Leukemia ProteinModelingModern ManMolecular ConfigurationMolecular ConformationMolecular InteractionMolecular StereochemistryMultiple lineage leukemia 1MutationMyelogenousMyeloidMyeloid-Lymphoid Leukemia GeneMyeloid-Lymphoid Leukemia ProteinMyeloid/Lymphoid Leukemia GeneMyeloid/Lymphoid Or Mixed Lineage Leukemia ProteinMyeloid/Lymphoid or Mixed Lineage Leukemia GeneNPMNPM1NPM1 geneNucleolar Phosphoprotein B23Oncogene ProductsOncogene ProteinsOncogenicOncoproteinsOutputPatientsPb elementPhase 1 Clinical TrialsPhase 2 Clinical TrialsPhase I Clinical TrialsPhase II Clinical TrialsPoliciesPrincipal InvestigatorPrognosisProgrammed Cell DeathProliferatingProtacProtein TurnoverProteinsProteolysis targeting chimericProteomicsProto Oncogene Proteins MLLRNA ExpressionRefractoryRegulationRegulatory Protein DegradationRelapseResistanceResistance developmentResistant developmentRoleStrains Cell LinesStretchingTestingTherapeuticTranscriptionTranscription Initiation SiteTranscription Start SiteTreatment EfficacyUbiquitin Ligase Component GeneUbiquitin Ligase GeneUbiquitin Protein LigaseUbiquitin-Protein Ligase ComplexesUbiquitin-Protein Ligase E3WritingZinc Finger Protein HRXacute granulocytic leukemiaacute granulocytic leukemia cellacute myeloblastic leukemia cellacute myelocytic leukemia cellacute myelogenous leukemia cellacute myeloid leukemiaacute myeloid leukemia cellacute nonlymphocytic leukemia celladulthoodconformationconformationalconformational stateconformationallyconformationscultured cell linedetermine efficacydeveloping resistancedevelopmentalefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationepigeneticallyevaluate efficacyexamine efficacygenetically engineered cellsgenetically modified cellsgenome mutationgenome scalegenome-widegenomewideheavy metal Pbheavy metal leadhematopoietic genehigh riskhistone H3 methyltransferasehistone methylasehistone methyltransferasehistone modificationimprovedin vivoinhibitorinnovateinnovationinnovativeintervention efficacykidsleukemiamembermixed lineage leukemia 1mutantnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachnucleolar protein B23nucleophosmidnucleophosminpediatricpharmacologicphase I protocolphase II protocolpre-clinical efficacypreclinical efficacypreventpreventingprogramsprotein B23protein complexprotein degradationproteolysis targeting chimaeraproteolysis targeting chimeraresistantsmall molecular inhibitorsmall moleculesmall molecule inhibitorsocial rolesuccesstherapeutic efficacytherapeutic targettherapy efficacyubiquitin ligaseubiquitin-protein ligaseyoungster
Description preview
Abstract Project 3
Acute myeloid leukemia (AML), and specifically KMT2A-rearranged (KMT2A-r) and NPM1 mutant AML, remain
devasting disease with an overall poor prognosis for high risk pediatric and adult patients. AML is characterized
by aberrant transcriptional programs caused by dysregulated chromatin associated complexes. In particular, the…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click